Advertisement

Topics

FDA knocks back Mylan's Advair generic for second time

04:57 EDT 14 Jun 2018 | Pharmafile

The FDA has rejected Mylan’s generic version of GlaxoSmithKline’s Advair for the second time following its knockback last year, citing “minor deficiencies” in its efficacy as reason for the decision.

read more

Original Article: FDA knocks back Mylan's Advair generic for second time

NEXT ARTICLE

More From BioPortfolio on "FDA knocks back Mylan's Advair generic for second time"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

GlaxoSmithKline
GlaxoSmithKline is the third largest pharmaceutical company in the world, based on annual sales, which reached $37,134m in 2009. Spread over 100 countries, GSK employs 96,500 people, 13,000 of which are dedicated to research and development of the the ...